Buying a pharmacy in France 2026: the complete installation guide

Acquiring a pharmacy is one of the most structuring financial transactions a French pharmacist will ever undertake. It is rarely just a goodwill purchase: it is a patrimonial, fiscal, legal, social, real estate and professional project that commits the owner for 10 to 20 years, with debt typically ranging from EUR 800,000 to EUR 3 million.

In 2026, the installation context has changed substantially. The reform of professional practice companies (ordonnance no. 2023-77 of 8 February 2023) has clarified ownership rules. Consolidation and accelerated divestments have driven the number of pharmacies down (≈ 20,000 in metropolitan France in 2026 vs more than 22,000 in 2018). Specialised banks now concentrate on well-structured, professional files. Average valuations have eased after post-Covid peaks but remain high. And acquisition taxation — registration duties, seller capital gains, debt cost — weighs increasingly in the total cost of ownership.

This guide answers, point by point, every question raised by an associate pharmacist, a recent graduate, an experienced buyer or an industry pharmacist planning to install themselves in France in 2026. It complements our complete pharmacy & officine accounting guide, which focuses on operations, by zooming on the upstream phase: decision, structure, valuation, negotiation, financing, first year.

Key idea: a successful installation in 2026 is not won at signing — it is won 6 to 12 months before, through file quality, business plan, structure design and due diligence with a specialised pharmacy accountant.

1.1 A consolidating market#

The number of pharmacies in metropolitan France keeps falling. This consolidation results from several structural factors:

• Demographic quota: opening a pharmacy requires meeting a population threshold (article L.5125-3 of the Public Health Code) — practically, one pharmacy per 2,500 inhabitants minimum, plus 4,500 inhabitants for any additional pharmacy in the same town.
• Encouraged consolidation: pharmacists are incentivised to merge rather than close, which lifts well-located pharmacy values and depresses those in declining areas.
• Owner demographics: nearly 30 % of practising owners are above 60, generating a structural pipeline of acquisition opportunities.

For a future owner, this means two things: opportunities exist, but scarcity pulls prices up in attractive locations (urban centres, dynamic suburbs, medical hubs). Conversely, rural pharmacies sometimes trade at 50–70 % of net revenue, but with sustainability risk.

1.2 Which buyer profile fits which pharmacy?#

Key idea: first-time installations almost always benefit from targeting a pharmacy slightly below the buyer's ambition — to build an improvement trajectory and preserve a second-investment capacity.

1.3 The 2026-specific stakes#

Three major topics influence every 2026 acquisition analysis:

1. Serialisation and digital compliance (FMD, e-prescription) — non-equipped pharmacies carry a hidden upgrade cost of EUR 8,000 to 25,000.
2. Business model evolution: dispensing fees, vaccination, shared care plans and TROD have rebalanced the margin structure but increased administrative load.
3. Buying group consolidation: belonging to a buying group (LDP, Leadersanté, Pharmavie, etc.) influences both valuation and margin — a systematic check with a specialised pharmacy accountant is essential.

The structure choice is the most structuring decision of the project. It drives taxation, remuneration, financing, social protection and future transmission.

2.1 Sole practice: EI and BNC regime#

Practising as a sole proprietor (EI) remains possible but is increasingly marginal in 2026 for a pharmacy acquisition. Profits are taxed under the BNC regime at personal income tax rates, the owner is TNS under URSSAF PAMC, and all profitability is taxed immediately.

Avoid if:

• the acquisition price exceeds EUR 600,000;
• you plan a second pharmacy;
• you target a family or progressive transmission;
• your marginal tax bracket exceeds 30 %.

2.2 SELARL: the historical pharmacy vehicle#

The Société d'Exercice Libéral à Responsabilité Limitée (SELARL) remains in 2026 the most common vehicle for a first installation. It is governed by Law no. 90-1258 of 31 December 1990, deeply revised by ordonnance 2023-77.

Advantages:

• Corporate income tax (15 % up to EUR 42,500 of profit, 25 % above).
• Flexibility between salary and dividends.
• Personal patrimony shielded.
• Goodwill repayment over 7 to 12 years through deductible interest and dividend upstreaming.

Drawbacks:

• TNS status of the majority manager: high CAVP + URSSAF social contributions on remuneration and on the dividend portion exceeding 10 % of share capital + current accounts.
• More formalism (general meetings, accounts filing, beneficial owners register).

2.3 SELAS: a rising choice#

The SELAS has gained traction since 2023, the ordonnance having lifted several ownership ambiguities.

Recommendation 2026: SELAS suits multi-partner projects or dividend-driven strategies (especially via SPFPL). SELARL remains more cost-efficient socially for a sole owner.

2.4 SPFPL: the pharmacist holding#

The Société de Participations Financières de Profession Libérale (SPFPL) has become the cornerstone of investment and transmission strategies since the 2023 reform. It can hold up to 100 % of SEL companies and, via the mother-daughter regime (article 145 CGI) and tax consolidation (article 223 A CGI), upstream dividends from operating SELs to the holding with only 1.25 % residual taxation.

Use cases:

• Acquire a pharmacy via debt held at SPFPL level.
• Prepare a second pharmacy acquisition.
• Anticipate transmission via a Pacte Dutreil.
• Onboard an associate pharmacist without operational dilution.

Key idea: the SPFPL + SELARL/SELAS combination is, in 2026, the reference structure for any 10-year-horizon pharmacist. The arbitration must be made before signing — never after. Our holding vs SCI guide clarifies the holding mechanics in France.

2.5 Quick decision matrix#

3.1 The three reference methods#

Method 1 — Percentage of net revenue (CA HT): The historical method. In 2026, the range is 70 % to 110 % of CA HT excluding rebates, modulated by location, clientele quality, real gross margin (≥ 31 % = bonus, < 27 % = malus), diversification and quota tightness.

Method 2 — Restated EBITDA multiple: The dominant method among financiers. Restated EBITDA = book EBITDA + normalised owner remuneration + ad hoc adjustments (private expenses, spousal salary, exceptionals). Typical multiple in 2026: 5.5 to 8 × restated EBITDA.

Method 3 — Patrimonial / DCF: Used for atypical pharmacies (large parapharmacy, fast growth, contractual buying group integration). DCF projects free cash flows over 5–7 years with an 8–12 % discount rate.

Key idea: a sound price converges within ± 8 % across the three methods. If only one method justifies the price, that is an overvaluation signal. Our business valuation guide details the restated EBITDA mechanics.

3.2 Mandatory restatements#

Before applying any multiple, restate:

1. The seller's remuneration vs market (typically EUR 70,000 to 95,000 for a TNS manager).
2. Rents vs market rent (especially when the property belongs to the seller via a SCI).
3. Private expenses booked as expenses.
4. Inventory overvaluation (slow-moving, expiring, supply-tense items).
5. One-off ROSP fees (vaccination campaigns).
6. Underestimated charges (ageing IT, FMD compliance upgrade).

3.3 2026 valuation ranges by profile#

Due diligence secures the investment. Too often neglected, it typically reveals 5 to 12 % drift on the asking price.

4.1 Axis 1 — Licence, ARS authorisation and Ordre compliance#

Verify the officine licence (article L.5125-9 CSP), absence of pending ARS proceedings, the seller's Ordre registration, and inspection history.

4.2 Axis 2 — Accounting and margins#

Analyse the last 3 sets of accounts plus general ledger and trial balance, with restatements: gross margin breakdown (drugs / OTC / parapharmacy / medical equipment), VAT consistency across the 2.1 % / 5.5 % / 10 % / 20 % rates, ROSP history, private expense detection.

4.3 Axis 3 — Inventory#

Inventory often represents 8 to 14 % of total price. Value at WAC (weighted average cost) HT, correct for expiring and slow-moving items, audit contradictorily on D-1 of the takeover.

4.4 Axis 4 — Employment and HR#

Audit employment contracts, classification under the French pharmacy collective agreement, accumulated seniority (social liability), HR compliance, prud'hommes litigation, long-term sick leaves and disability cases.

4.5 Axis 5 — Commercial lease#

The lease drives sustainability. Check residual duration, specialisation clause (pharmacy of officine), rent vs market, renewal and indexation clauses, possible separate property ownership via a SCI.

4.6 Axis 6 — Technical and digital compliance#

Often underestimated: up-to-date LGO, FMD serialisation compliance, operational e-prescription, documented GDPR (register, notices, processors), transferable software licences and maintenance.

Key idea: a thorough due diligence by a specialised valuation and acquisition accountant typically renegotiates 4 to 8 % off the asking price — i.e. EUR 40,000 to 150,000 on a standard pharmacy.

5.1 The typical capital stack#

The personal contribution may take several forms: personal savings, employee savings unlock, structured family loans, anticipated donations, or reinvestment after a previous pharmacy resale.

5.2 Specialised banks#

A few banks operate dedicated pharmacy desks. They expect a complete file: 5-year business plan with restated assumptions, monthly cash plan over 24 months, catchment area study, formalised due diligence, coherent legal structure, possibly a Bpifrance-OSEO guarantee for first installations.

5.3 Typical repayment plan#

For an EUR 1.8 m acquisition financed at 80 %:

• Debt: EUR 1.44 m
• Term: 12 years
• 2026 indicative rate: ≈ 4.5 % to 5 %
• Annuity: ≈ EUR 160,000 to 170,000 / year
• Required repayment capacity: restated EBITDA ≥ EUR 220,000

Key idea: for a project to be "bankable" in 2026, the target's restated EBITDA must cover at least 1.3 × debt annuity, accounting for owner minimum remuneration (≈ EUR 6,000 net/month) and related taxation.

5.4 Vendor loan and earn-out: negotiation levers#

A vendor loan (the seller defers part of the price) often unlocks deals: it reassures the bank, reduces the personal contribution and is generally repaid over 3–5 years at moderate rates.

An earn-out (price top-up indexed on future performance) is useful when uncertainty weighs on valuation (a key prescriber retiring, regulatory shift, business pivot).

6.1 Registration duties (buyer's burden)#

Goodwill acquisition is subject to registration duties (article 719 CGI):

Worked example: for a pharmacy sold at EUR 1,600,000, duties:

• (200,000 − 23,000) × 3 % = EUR 5,310
• (1,600,000 − 200,000) × 5 % = EUR 70,000
• Total ≈ EUR 75,310 to budget on top of the price.

6.2 Acquisition of SEL shares#

If you buy shares of an existing SEL (instead of the goodwill), the regime differs: 0.1 % on SELAS shares and 3 % on SELARL parts after rebate (article 726 CGI), with caps — a major saving versus a goodwill purchase.

Key idea: structuring as a share deal rather than an asset deal can cut registration duties by more than 90 %. This must be reviewed with a specialised legal counsel since it implies taking over the entire liability stack.

6.3 VAT on the acquisition#

Pharmacy goodwill acquisition is in principle VAT-exempt (article 257 bis CGI) when the activity is continued — almost always the case. No VAT to budget on the price.

6.4 Seller's taxation (relevant for negotiation)#

Knowing the seller's taxation clarifies negotiation room: capital gains taxation, possible exemptions (151 septies A CGI on retirement, 238 quindecies CGI on small businesses), SPFPL-driven optimisations (mother-daughter, merger).

7.1 The four key steps#

7.2 Mandatory conditions precedent#

• Bank financing under defined conditions.
• Registration with the Ordre national des pharmaciens.
• ARS licence transfer authorisation if required.
• Revenue maintenance between signing and closing (reverse earn-out clause).
• Final contradictory inventory audit.

7.3 Administrative steps to anticipate#

• Registration with the Ordre national des pharmaciens (section A).
• Affiliation with CAVP (mandatory pension) and URSSAF PAMC or general regime depending on the structure.
• Company registration (SELARL/SELAS) with RCS and beneficial owners register (RBE) at INPI.
• Notification to the French health insurance for opening reimbursement flows.
• Update of employment contracts (transfer per article L.1224-1 of the Labour Code).

Key idea: coordinating these steps is one of the core value-adds of a specialised pharmacy accountant. Any delay can push the takeover by weeks.

8.1 Principle#

A management lease allows a pharmacist to operate the goodwill before owning it. Strictly framed by article L.5125-21 of the Public Health Code and article L.144-1 et seq. of the Commercial Code.

Use cases:

• Death or disability of the owner pending heir takeover.
• Progressive transmission.
• Temporarily incapacitated owner.

8.2 Benefits and limits#

Benefits:

• Activity start without down payment or initial debt.
• Real-life test before acquisition.
• Lighter cash needs.

Limits:

• Limited duration (usually 2 to 5 years, renewable once).
• Royalty payable to the owner (often 4 to 8 % of net revenue).
• No goodwill amortisation (no ownership).
• Strict conditions (the lessor must have operated the pharmacy ≥ 7 years).

8.3 Articulation with a future acquisition#

A management lease is an excellent pre-acquisition gateway: it lets the buyer settle in, stabilise the clientele and refine financing needs. Many 2026 deals start with 18 to 30 months of management lease before a final buyout — often pre-negotiated.

9.1 Accounting setup and reporting#

From day one, the accountant deploys a pharmacy-specific chart of accounts (sub-accounts by VAT rate, product category and health mission), a monthly dashboard (gross margin, EBITDA, working capital, ROSP), a rolling 13-week cash plan to manage VAT, IS, social contributions and bank annuity, plus a quarterly review with arbitrations.

For operational follow-up, Pennylane or a connected LGO enables semi-automated bookkeeping and real-time KPI flow.

9.2 Immediate remuneration optimisation#

The new owner's remuneration must be steered from month one: salary vs dividend arbitration in TNS SELARL, dividend upstreaming to SPFPL to repay acquisition debt, PER or Madelin retirement plan setup, suitable TNS health and disability cover.

Our director remuneration simulator quickly tests trade-offs. For payroll cost on pharmacy staff, the employer cost calculator clarifies the hiring of an additional preparator or associate pharmacist.

9.3 Gross margin steering#

Gross margin is the year-one KPI. Three levers: purchasing policy and wholesaler choice (direct lab vs distribution wholesaler — 1.5 to 3 margin points), product mix (parapharmacy at 20 % VAT and free margin, medical equipment at 5.5 %), and inventory management (rotation, supplier terms, expiring stock).

9.4 VAT mastery#

Pharmacy VAT is one of the trickiest first-year topics. Four rates coexist:

• 2.1 % on reimbursable drugs and certain fees;
• 5.5 % on selected medical devices;
• 10 % on selected non-reimbursable products;
• 20 % on parapharmacy, cosmetics and miscellaneous services.

Wrong LGO VAT parameterisation is the no. 1 mistake for new owners. A parameterisation audit within the first 3 months is mandatory. Our VAT calculator helps validate monthly returns quickly.

The success gap between two comparable installations rarely comes from the purchase price. It comes from three upstream decisions: the choice of structure (SPFPL or not, SELARL or SELAS), the depth of due diligence, and the rigour of first-year management.

In 2026, owners who succeed long term share three traits:

1. They anticipate the structure 6 to 12 months before signing, embedding the transmission angle from day one.
2. They run a deep due diligence, ready to walk away on insufficient restated margins.
3. They establish serious monthly reporting from month one, with quarterly structured dialogue with their accountant.

Conversely, the gravest difficulties almost always come from over-trusting seller's figures, an inadequate legal structure suffered rather than chosen, or improvised cash management during the early months.

The most poorly anticipated risk is dividend taxation when the SELARL is held by an SPFPL. The mother-daughter regime upstreams 95 % of dividends tax-exempt to the SPFPL — but dividends paid to the pharmacist as a private individual (from the SPFPL or directly from the SEL) are subject to:

• the PFU (flat tax) at 30 % or progressive income tax + social levies;
• on the SELARL dividend portion exceeding 10 % of capital + current accounts + share premium, TNS contributions under PAMC, which can exceed 40 %.

The classic mistake is to plan on a 30 % flat tax while the real cost on the excess portion can reach 55–60 % including TNS contributions. A rigorous, yearly-recalibrated salary-vs-dividend arbitration is mandatory.

Before signing the preliminary deed, the future owner must have settled six decisions:

1. Structure: standalone SELARL, standalone SELAS, or SPFPL + SEL?
2. Acquisition mode: goodwill or shares?
3. Real estate: separate property acquisition via SCI?
4. Personal contribution: amount, origin, articulation with a possible family pact?
5. Starting remuneration: precise target, salary/dividend arbitration?
6. Transmission horizon: 10, 15 or 20 years, with or without a Pacte Dutreil?

Key idea: these six decisions must be documented in a strategic note co-signed by the owner, the accountant and the lawyer. That document secures the entire forward trajectory.

• SEL reform (ordonnance 2023-77): some pre-existing statutory clauses are now void. Any acquisition of existing SEL shares must include a full statutes review.
• Interest rate environment: despite expected modest easing, financing a French pharmacy in 2026 remains more expensive than in 2021. Business plans must factor a debt cost ≥ 4.5 %.
• FMD serialisation: technical non-compliance of a target must be precisely costed (equipment + training).
• Cession wave: owners' demographic pyramid accelerates the deal flow; read the local market before pricing.
• Dispensing fees and new missions: their share in profit keeps rising — restate properly in valuation.

• Patrimonial project framing on 10–15 years with the accountant
• Documented structure choice (SELARL / SELAS / SPFPL)
• Validated catchment area study
• Letter of intent drafted by lawyer
• Last 3 sets of accounts and tax returns analysed
• HR audit (liabilities, classifications, litigation)
• Lease audit (sensitive clauses)
• Compliance audit (LGO, serialisation, GDPR, ARS)
• Contradictory inventory scheduled
• Internally validated bank business plan
• Secured contribution (savings, donation, family pact)
• Funding requests filed with 2 to 3 banks
• Complete conditions precedent in the preliminary deed
• SELARL/SELAS and SPFPL incorporation if required
• Ordre + ARS + URSSAF PAMC registration
• Monthly reporting and 13-week cash plan in place
• LGO VAT parameterisation audit at M+3